Roquefort Therapeutics plc is a listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market prior to partnering or selling to big pharma
We are progressing five novel patent-protected pre-clinical anti-cancer medicines through a combination of partnerships with leading academic cancer research centres and a state of the art laboratory in Stratford-upon-Avon.
Our leadership team has proven track record in drug development, regulatory approvals and biotech transactions.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and in December 2022 acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
